Randy Poelman1, Isabelle Schuffenecker2, Coretta Van Leer-Buter3, Laurence Josset4, Hubert G M Niesters3, Bruno Lina4. 1. The University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Virology, Groningen, The Netherlands. Electronic address: r.poelman@umcg.nl. 2. National Enterovirus Reference Centre, Laboratoire de Virologie, Centre de Biologie Est des Hospices Civils de Lyon, Bron, France. 3. The University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Virology, Groningen, The Netherlands. 4. National Enterovirus Reference Centre, Laboratoire de Virologie, Centre de Biologie Est des Hospices Civils de Lyon, Bron, France; Virpath Lab, EA4610, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon1, Université de Lyon, Lyon, France.
Abstract
BACKGROUND: In August and September 2014, unexpected clusters of enterovirus-D68 (EV-D68) infections associated with severe respiratory disease emerged from North-America. In September, the European Centre for Disease Prevention and Control (ECDC) asked European countries to strengthen respiratory sample screening for enterovirus detection and typing in cases with severe respiratory presentations. OBJECTIVES: To provide a detailed picture of EV-D68 epidemiology in Europe by conducting a retrospective and prospective laboratory analysis of clinical specimens. STUDY DESIGN: An initiative supported by the European Society for Clinical Virology (ESCV) and ECDC was launched to screen for EV-D68 in respiratory specimens between July 1st and December 1st 2014 in Europe and to sequence the VP1 region of detected viruses for phylogenetic analytic purposes. RESULTS: Forty-two institutes, representing 51 laboratories from 17 European countries, analyzed 17,248 specimens yielding 389 EV-D68 positive samples (2.26%) in 14 countries. The proportion of positive samples ranged between 0 and 25% per country. These infections resulted primarily in mild respiratory disease, mainly detected in young children presenting with wheezing and in immuno-compromised adults. The viruses detected in Europe are genetically very similar to those of the North-American epidemic and the majority (83%) could be assigned to clade B. Except for 3 acute flaccid paralysis (AFP) cases, one death and limited ICU admissions, no severe cases were reported. CONCLUSIONS: The European study showed that EV-D68 circulated in Europe during summer and fall of 2014 with a moderate disease burden and different pathogenic profile compared to the North-American epidemic.
BACKGROUND: In August and September 2014, unexpected clusters of enterovirus-D68 (EV-D68) infections associated with severe respiratory disease emerged from North-America. In September, the European Centre for Disease Prevention and Control (ECDC) asked European countries to strengthen respiratory sample screening for enterovirus detection and typing in cases with severe respiratory presentations. OBJECTIVES: To provide a detailed picture of EV-D68 epidemiology in Europe by conducting a retrospective and prospective laboratory analysis of clinical specimens. STUDY DESIGN: An initiative supported by the European Society for Clinical Virology (ESCV) and ECDC was launched to screen for EV-D68 in respiratory specimens between July 1st and December 1st 2014 in Europe and to sequence the VP1 region of detected viruses for phylogenetic analytic purposes. RESULTS: Forty-two institutes, representing 51 laboratories from 17 European countries, analyzed 17,248 specimens yielding 389 EV-D68 positive samples (2.26%) in 14 countries. The proportion of positive samples ranged between 0 and 25% per country. These infections resulted primarily in mild respiratory disease, mainly detected in young children presenting with wheezing and in immuno-compromised adults. The viruses detected in Europe are genetically very similar to those of the North-American epidemic and the majority (83%) could be assigned to clade B. Except for 3 acute flaccid paralysis (AFP) cases, one death and limited ICU admissions, no severe cases were reported. CONCLUSIONS: The European study showed that EV-D68 circulated in Europe during summer and fall of 2014 with a moderate disease burden and different pathogenic profile compared to the North-American epidemic.
Authors: Victoria L Gilrane; Jian Zhuge; Weihua Huang; Sheila M Nolan; Abhay Dhand; Changhong Yin; Christian Salib; Faariah Shakil; Helen Engel; John T Fallon; Guiqing Wang Journal: J Clin Microbiol Date: 2020-08-24 Impact factor: 5.948
Authors: Kevin Messacar; Edwin J Asturias; Alison M Hixon; Coretta Van Leer-Buter; Hubert G M Niesters; Kenneth L Tyler; Mark J Abzug; Samuel R Dominguez Journal: Lancet Infect Dis Date: 2018-02-23 Impact factor: 25.071
Authors: Emma B Hodcroft; Robert Dyrdak; Cristina Andrés; Adrian Egli; Josiane Reist; Diego García Martínez de Artola; Julia Alcoba-Flórez; Hubert G M Niesters; Andrés Antón; Randy Poelman; Marijke Reynders; Elke Wollants; Richard A Neher; Jan Albert Journal: PLoS Pathog Date: 2022-05-31 Impact factor: 7.464
Authors: A I Carrion Martin; R G Pebody; K Danis; J Ellis; S Niazi; S DE Lusignan; K E Brown; M Zambon; D J Allen Journal: Epidemiol Infect Date: 2017-04-03 Impact factor: 4.434
Authors: Matthew R Vogt; Jianing Fu; Nurgun Kose; Lauren E Williamson; Robin Bombardi; Ian Setliff; Ivelin S Georgiev; Thomas Klose; Michael G Rossmann; Yury A Bochkov; James E Gern; Richard J Kuhn; James E Crowe Journal: Sci Immunol Date: 2020-07-03